BerGenBio ASA

OB:BGBIO Stock Report

Market Cap: NOK 64.1m

BerGenBio Future Growth

Future criteria checks 0/6

BerGenBio's revenue is forecast to decline at 150.1% per annum while its annual earnings are expected to grow at 12.9% per year. EPS is expected to grow by 12.8% per annum. Return on equity is forecast to be -2.2% in 3 years.

Key information

12.9%

Earnings growth rate

12.8%

EPS growth rate

Biotechs earnings growth16.4%
Revenue growth rate-150.1%
Future return on equity-2.2%
Analyst coverage

Low

Last updated06 Mar 2025

Recent future growth updates

Recent updates

We Think BerGenBio (OB:BGBIO) Needs To Drive Business Growth Carefully

Jan 06
We Think BerGenBio (OB:BGBIO) Needs To Drive Business Growth Carefully

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Sep 21
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

Jun 02
Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

Dec 07
Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Aug 24
BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Feb 06
BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Sep 26
Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Jun 11
Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Feb 17
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

Sep 21
We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

Mar 13
It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Feb 11
We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

Dec 21
What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

Earnings and Revenue Growth Forecasts

OB:BGBIO - Analysts future estimates and past financials data (NOK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-111N/AN/A2
12/31/2025N/A-80-108-1052
12/31/20241-139-153-153N/A
9/30/20241-152-139-139N/A
6/30/20241-155-176-176N/A
3/31/20241-155-192-192N/A
12/31/20230-190-225-225N/A
9/30/20230-226-281-281N/A
6/30/20230-258-282-282N/A
3/31/20230-293-289-289N/A
12/31/20220-302-288-288N/A
9/30/20221-294-290-290N/A
6/30/20221-304-294-294N/A
3/31/20221-309-307-307N/A
12/31/20211-309-303-303N/A
9/30/20211-314-280-280N/A
6/30/20211-311-280-280N/A
3/31/20211-290-246-246N/A
12/31/20201-257-234-234N/A
9/30/20200-241-216-216N/A
6/30/20200-218-187-187N/A
3/31/20200-204-190-190N/A
12/31/20199-199-187-187N/A
9/30/201911-193-186-186N/A
6/30/201911-186-189-189N/A
3/31/201911-182-201-201N/A
12/31/20182-192-187-187N/A
9/30/2018N/A-188N/A-179N/A
6/30/2018N/A-186N/A-178N/A
3/31/2018N/A-171N/A-143N/A
12/31/2017N/A-182N/A-168N/A
9/30/2017N/A-162N/A-164N/A
6/30/2017N/A-142N/A-140N/A
3/31/2017N/A-175N/A-173N/A
12/31/2016N/A-130N/A-124N/A
9/30/2016N/A-127N/A-121N/A
6/30/2016N/A-128N/A-119N/A
3/31/2016N/A-82N/A-71N/A
12/31/2015N/A-72N/A-63N/A
9/30/2015N/A-70N/A-61N/A
6/30/20150-64N/A-59N/A
3/31/20151-57N/A-56N/A
12/31/20141-58N/A-54N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BGBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BGBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BGBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BGBIO is forecast to have no revenue next year.

High Growth Revenue: BGBIO is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BGBIO is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/24 02:26
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BerGenBio ASA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ulrik TrattnerCarnegie Investment Bank AB
Geir HolomDNB Markets
Sean ConroyEdison Investment Research